Shanhong Guan

Shanhong Guan is a seasoned professional in the field of biostatistics, currently serving as Vice President and Head of Biometrics at ALX Oncology since April 2021, following roles as Executive Director and Senior Director within the same department. Previously, Shanhong Guan held the position of Director of Biostatistics at Nektar Therapeutics, contributing to the clinical development of the Immuno-Oncology compound Bempegaldesleukin. Experience also includes serving as Associate Director of Biostatistics at Pharmacyclics, supporting the development of Ibrutinib, and managing biostatistical activities for various oncology and cardiovascular projects at Gilead Sciences and Sanofi. Early career stages involved contributions at Merck, Novartis, and Covance, focusing on cancer trials and statistical methodologies. Shanhong Guan earned a Ph.D. in Statistics from the University of Wisconsin-Madison.